Short answer
MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) filed its Q3 2025 10-Q quarterly report on Nov 7, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $42M (down 36.2% year over year) with net income of −$26M.
Q3 2025 key financials · XBRL
- Revenue
- $42M
- −36.2% YoY · −12.2% QoQ
- Net income
- −$26M
- +74.2% YoY · +35.4% QoQ
- Operating margin
- -98.6%
- Gross margin
- 50.8%
- EPS (diluted)
- −$0.18
- +75.0% YoY · +33.3% QoQ
Source: XBRL data from the MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) Q3 2025 10-Q on SEC EDGAR. USD.
MARAVAI LIFESCIENCES HOLDINGS, INC. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $41.6M, down from $69.0M YoY
- Nucleic Acid Production revenue $25.4M vs $53.8M; Biologics Safety Testing $16.3M vs $15.2M
- Q3 revenue included no high-volume CleanCap sales, versus $18.2M YoY
- Acquisition of Molecular Assemblies assets for $11.2M in January 2025
- SG&A $35.4M vs $39.1M YoY; R&D $3.8M vs $4.7M
Risk Factors
- New organizational-change risk triggered by June 2025 CEO and CFO appointments
- Workforce-reduction risk from August 2025 plan targeting approximately 25% of employees
- Financial risk from potentially higher-than-anticipated restructuring and severance costs
- Operational risk from employee attrition, lower morale, and business disruption
- Cash-flow risk from delayed or unrealized cost savings and possible additional workforce reductions
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other MARAVAI LIFESCIENCES HOLDINGS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.